Ormeval provides decision-support intelligence derived from public sources. It is not investment, medical, legal or regulatory advice, and states nothing about the value of any security. Forward figures are deterministic model estimates, not guidance.
Ormeval · Pharma intelligence · 28 SEP 2026
Company
The number on slide four is two quarters old. Everyone in the room knows it, nobody can prove it, and the meeting moves on. That was the ordinary state of commercial intelligence in every franchise I ran: expensive, confident, and hard to check on the day it mattered.
Ormeval is built for that day. Every reported figure on the platform traces to a primary source and links to it. Every estimate is labelled as an estimate. Every forecast is dated, frozen in a public ledger before the outcome it predicts, and graded when the outcome arrives, misses first. It reads to the role, whether you run a portfolio, a franchise or a country, and it answers agents as readily as people.
The mission is simple to state: better health, faster. Launch, lifecycle and resource decisions are made faster, and better, when the people making them can see what moved and check why.
Le chiffre de la quatrième diapositive date de deux trimestres. Tout le monde dans la salle le sait, personne ne peut le prouver, et la réunion continue. C'était l'état ordinaire de l'intelligence commerciale dans chaque franchise que j'ai dirigée : coûteuse, sûre d'elle, et difficile à vérifier le jour où cela comptait.
Ormeval est construit pour ce jour-là. Chaque chiffre rapporté sur la plateforme remonte à une source primaire et y renvoie. Chaque estimation est étiquetée comme telle. Chaque prévision est datée, figée dans un registre public avant le résultat qu'elle prédit, puis notée lorsque le résultat arrive, les écarts en premier. Elle se lit selon le rôle, que vous dirigiez un portefeuille, une franchise ou un pays, et elle répond aux agents aussi bien qu'aux personnes.
La mission tient en trois mots : mieux soigner, plus vite. Les décisions de lancement, de cycle de vie et d'allocation se prennent plus vite, et mieux, quand ceux qui les prennent voient ce qui a bougé et peuvent vérifier pourquoi.
A modern oncology or specialty asset can span twenty or more indications, each at a different stage, each with its own competitive set and its own catalyst calendar. Keeping that picture current is a full-time job, and the moment a competitor reads out a Phase III, files in a new geography, or hits a regulatory setback, the picture changes. Most teams reconstruct this by hand, in slide decks that take days to build and are stale within a quarter.
The cost isn't just time; it's walking into a planning meeting without knowing what moved.
Ormeval collapses that work into a continuously updated cockpit. A CEO sees portfolio-level signal: which assets are gaining indications, which face loss of exclusivity, where rivals are advancing. A franchise head sees the lifecycle picture for a single molecule: every approved and under-study indication, the competitive landscape, regional entry, and the readouts that drive the next cycle. A general manager filters to their geography and sees exactly what changed this quarter. Same underlying data, framed for the decision in front of you.
This product is built on the assumption that you will check it. Reported figures link to the public record they came from - and a figure that claims a source we cannot verify is automatically downgraded to an estimate, never silently kept (0 such figures survive across 615 assets). Forecasts come from a deterministic engine, are labelled as model estimates, and are scored on our track record page against what companies actually reported: largest misses first, benchmarked against naive extrapolation, with the regimes where a two-line trailing extrapolation beats our engine named in a table rather than blended away. 5,395 forecasts across 413 drugs are frozen in an append-only ledger and scored only when reality arrives - the first out-of-sample scores land with FY2027 reporting and will be published whatever they say. Comparisons we refuse to score (alliance bookings, partner revenue) are listed with the 10-K language that disqualifies them. Ask any other provider for the same table.
We never scrape investor sites at runtime, never ingest proprietary or paywalled data, and never let a language model invent a figure. If we can't verify a date, we leave it out rather than guess. That discipline is the whole point: intelligence you can cite in a boardroom.
Ormeval runs on a deterministic engine, not a language model asked to guess. Every reported figure is a fact read from a primary source - a filing, a label, a registry - and linked to it, never generated. Forward numbers come from the engine alone, labelled as model estimates, never edited or invented by a language model. Each forecast is dated, frozen before the outcome it predicts, and left untouched: nothing revises a call after the fact. Grading starts in public when 2027 results are reported, misses listed first.
Ormeval fonctionne sur un moteur déterministe, jamais sur un modèle de langage invité à deviner. Chaque chiffre rapporté est un fait lu à la source primaire - un dépôt, une notice, un registre - et relié à celle-ci, jamais généré. Les chiffres prévisionnels proviennent uniquement du moteur, étiquetés comme estimations du modèle, jamais modifiés ni inventés par un modèle de langage. Chaque prévision est datée, figée avant le résultat qu'elle prédit, et laissée intacte : rien ne révise un appel après coup. L'évaluation publique commence lorsque les résultats de 2027 sont publiés, les échecs indiqués en premier.
Ormeval is built and operated by Charles Gourdeau. He was Global Oncology Franchise Operations and Strategy Lead at AstraZeneca from 19 April 2022 to 20 November 2025. Before that he held commercial leadership roles at Sanofi across Greater China and Latin America, and earlier served as a Trade Commissioner for the Government of Canada in Shanghai. He has spent more than a decade in pharmaceutical commercial strategy and operations, works in French, English, Mandarin and Spanish, and is based in Quebec City.
What carries over from that career is not data. It is a standard for what a checkable answer looks like: fast, sourced, and honest about the difference between a reported fact and a working assumption. That is why the deterministic engine, not a model and not us, owns every computed number.
Ormeval is an independent product. It is not affiliated with, sponsored by, or endorsed by any pharmaceutical company, and it is built without access to any company's confidential or proprietary information. Every figure is built only from the public sources described in our methodology, and where a company is named it appears only as the public subject of public facts.
Ormeval est construit et exploité par Charles Gourdeau. Il a été Global Oncology Franchise Operations and Strategy Lead chez AstraZeneca du 19 avril 2022 au 20 novembre 2025. Auparavant, il a occupé des fonctions de direction commerciale chez Sanofi en Chine élargie et en Amérique latine, et plus tôt il a été délégué commercial du gouvernement du Canada à Shanghai. Il compte plus de dix ans en stratégie et en opérations commerciales pharmaceutiques, travaille en français, en anglais, en mandarin et en espagnol, et vit à Québec.
Ce qui reste de ce parcours, ce ne sont pas des données. C'est une exigence sur ce qu'est une réponse vérifiable : rapide, sourcée, et honnête sur la différence entre un fait rapporté et une hypothèse de travail. C'est pourquoi le moteur déterministe, ni un modèle ni nous, détient chaque chiffre calculé.
Ormeval est un produit indépendant. Il n'est affilié à aucune société pharmaceutique, ni commandité ni approuvé par l'une d'elles, et il est construit sans accès à l'information confidentielle ou exclusive de quelque société que ce soit. Chaque chiffre provient uniquement des sources publiques décrites dans notre méthodologie, et lorsqu'une société est nommée, elle n'apparaît que comme sujet public de faits publics.
Have a question about the data, a coverage request, or an enterprise need? We'd love to hear from you. Get in touch.